治疗心力衰竭患者的铁缺乏症:什么,为什么,何时,如何,在哪里和谁
Fraser J Graham1, Kaushik Guha2, John G Cleland3
1British Heart Foundation Centre of Research Excellence, School of Cardiovascular & Metabolic Health, University of Glasgow, Glasgow, UK fraser.graham@glasgow.ac.uk.
Heart (British Cardiac Society)
|August 19, 2024
概括
铁缺乏症在心力衰竭患者中很常见. 静脉注射铁有效地治疗这种情况,改善健康状况并减少住院,但目前的诊断定义需要修订,以更好地针对患者.
科学领域:
- 心脏病学 心脏病学
- 血液学 血液学 血液学
- 内部医学 内部医学
背景情况:
- 缺铁在心力衰竭中普遍存在,心力衰竭有减少或轻微减少的射出分数.
- 它与症状严重程度的增加,生活质量的降低以及住院和死亡风险的增加有关.
- 静脉注射铁是一种安全有效的治疗选择.
研究的目的:
- 审查目前关于静脉注射铁在心力衰竭中的使用证据.
- 为了突出现有的铁缺乏症定义对这个患者群体的缺陷.
- 为未来的研究和临床实践提供建议.
主要方法:
- 关于对心力衰竭中静脉注射铁的研究的文献综述.
- 对心力衰竭患者缺铁的诊断标准的分析.
- 综合有关治疗反应和患者结果的证据.
主要成果:
- 静脉注射铁,使用铁性碳素或脱硫,改善了患者的健康状况,并减少了心力衰竭的住院治疗.
- 目前的诊断标准 (血清费里丁<100μg/L) 不足以确定可能受益的患者.
- 转林和率<20%是对静脉注射铁疗法的潜在反应的更好指标.
结论:
- 静脉注射铁是患有铁缺乏症的心力衰竭患者的宝贵疗法.
- 需要修订诊断标准,重点关注转林和,以进行最佳的患者选择.
- 对心脏病学家来说,进一步的研究和实践指南至关重要.
相关概念视频
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
405
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
405
Heart Failure Drugs: β-Blockers
324
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
324
Heart Failure Drugs: Diuretics
352
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
352
Heart Failure Drugs: Inotropic Agents
547
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
547
Pathophysiology of Heart Failure
1.5K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
189
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
189


